Login / Signup

The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?

Liliana MontellaMargaret OttavianoRocco MorraErica PietroluongoPietro De PlacidoMarianna TortoraChiara SorrentinoGaetano FacchiniSabino De PlacidoMario GiulianoGiovannella Palmieri
Published in: Cancers (2022)
Thymic epithelial tumors are rare tumors usually presenting as a mass located in the anterior mediastinum and/or with symptoms deriving from associated paraneoplastic syndromes. Unresectable platinum-refractory tumors are often treated with alternative regimens, including chemotherapeutic agents as well as chemo-free regimens. The most popular unconventional therapy is represented by the somatostatin analog octreotide, which can be used alone or with prednisone. The in vivo expression of somatostatin receptors documented by imaging with indium-labeled octreotide or gallium-68 Dotapeptides, the successful use of octreotide and prednisone in a chemo-refractory patient, and, thereafter, the experiences from a case series have enforced the idea that this treatment merits consideration-as proved by its inclusion in the National Comprehensive Cancer Network guidelines. In the present review, we analyze the preclinical basis for the therapeutic use of somatostatin and prednisone in refractory thymic tumors and discuss the available studies looking at future perspectives.
Keyphrases